1-(2,4-二氯苯基)-5-(4-甲氧基苯基)-4-甲基-N-(1-哌啶基)-1H-吡唑-3-甲酰胺
1-(2,4-二氯苯基)-5-(4-甲氧基苯基)-4-甲基-N-(1-哌啶基)-1H-吡唑-3-甲酰胺结构式
|
常用名 | 1-(2,4-二氯苯基)-5-(4-甲氧基苯基)-4-甲基-N-(1-哌啶基)-1H-吡唑-3-甲酰胺 | 英文名 | NIDA-41020 |
|---|---|---|---|---|
| CAS号 | 502486-89-7 | 分子量 | 459.36800 | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | C23H24Cl2N4O2 | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | N/A | |
| 符号 |
GHS06 |
信号词 | Danger |
|
Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists
Drug Discov. Today 10 , 693-702, (2005) The proven clinical efficacy of the CB1 cannabinoid receptor antagonist rimonabant in obesity and its further therapeutic potential has given a tremendous impetus to the discovery of novel CB1 antagonists. |
|
|
Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity.
J. Med. Chem. 46 , 642-645, (2003) Exploration of the central CB1 cannabinoid receptors using positron emission tomography (PET) will allow for an understanding of the pharmacological and physiological role played by these receptors in the CNS. Current tracers are highly lipophilic compounds t... |
期刊文献综述：
更多...